Osaic Holdings
RNAZ icon

Osaic Holdings’s TransCode Therapeutics RNAZ Stock Holding History

Osaic Holdings’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$20 – 8031
2025
Q4 		$20 Hold
3
– – ﹤0.01% 7740
2025
Q3 		$29 Hold
3
– – ﹤0.01% 7816
2025
Q2 		$23 Sell
3
-1
-25% -$9 ﹤0.01% 7654
2025
Q1 		$50 Buy
+4
New +$513 ﹤0.01% 7286

Other funds holding RNAZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Osaic Holdings's RNAZ Position: Q1 2026 in Review

Osaic Holdings sold out of TransCode Therapeutics (RNAZ) in Q1 2026, closing a stake of 3 shares — an estimated $20 sold.

Osaic Holdings first reported a position in RNAZ in Q1 2025 and held it in 4 quarters. The position peaked at $50 in Q1 2025. 8 funds tracked by Wall St. Rank hold RNAZ as of Q1 2026.

  • Osaic Holdings reported no remaining TransCode Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Osaic Holdings sold 3 TransCode Therapeutics shares in Q1 2026, an estimated $20.
  • Osaic Holdings first reported a position in TransCode Therapeutics in Q1 2025 and held it in 4 quarters.
  • Osaic Holdings's TransCode Therapeutics position peaked at $50 in Q1 2025.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.